Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease. (February 2019)

• Record Type: Journal Article
• Authors: Ma, Danning; Wong, Wendy; Aviado, Jeremie; Rodriguez, Cesar; Wu, Helen
• Is Part Of: American journal of gastroenterology. Volume 114:Number 2(2019)
• Publication Date: 2019-02
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Gastrointestinal Diseases -- Periodicals; Electronic journals; Periodicals; 616.33
• DOI: 10.1038/s41395-018-0368-1
• Languages: English
• ISSNs: 0002-9270

Abstract

Abstract : INTRODUCTION: Infliximab for inflammatory bowel disease (IBD) is FDA-approved to be administered 2 h or more. We adopted a new protocol to infuse infliximab over 1 h and in this study, we aimed to determine the safety of a 1-h infusion. METHODS: This retrospective cohort included adult IBD patients who received infliximab between June and December 2017 and compared reaction rates of 1-h maintenance infusions to that of 2-h maintenance infusions. RESULTS: A total of 551 infusions were administered to 179 patients. The infusion groups demonstrated no significant differences in reaction rates. CONCLUSIONS: Infliximab infusion over 1 h is well-tolerated.